مباشر

ScienceDid this scientist go too far trying to save Ecuador’s wildlife?Endpoints NewsASGCT dispatch: In vivo CAR-T is everywhere, but still preclinical Clinical OMICsPrior Heart Attack Linked to Faster Cognitive Decline Over Time BioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapies FierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS Endpoints NewsDrugmakers have to go through rigorous tests to get a lower tariff rate FierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest Bouncer Clinical OMICsContact Lenses Show Promise for Depression BioWorldFosun secures rights to Aribio’s AR-1001 in potential $4.7B deal BioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failure Endpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data

BioPharma Dive ١٤ مايو ٢٠٢٦

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and...

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.